Port Delivery System for Ranibizumab
Research payments
$30,841,455
Through program year 2025, $30,841,455 in research payments was reported against Port Delivery System for Ranibizumab, across 1,818 payments.
- Paid by (largest first)
- Genentech, Inc.; F. Hoffmann-La Roche AG
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
7 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $56,175 | 7 |
| 2024 | Research | $47,437 | 12 |
| 2023 | Research | $120,166 | 23 |
| 2022 | Research | $293,286 | 40 |
| 2021 | Research | $4,389,132 | 369 |
| 2020 | Research | $14,159,058 | 690 |
| 2019 | Research | $11,776,202 | 677 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Arshad Khanani Reno, NV Named on 50 payments
- David Brown Houston, TX Named on 46 payments
- Ivan Suner Tampa, FL Named on 40 payments
- Thomas Aaberg Atlanta, GA Named on 37 payments
- Sunil Gupta Pensacola, FL Named on 35 payments
- Chirag Jhaveri Austin, TX Named on 35 payments
- David Eichenbaum Saint Petersburg, FL Named on 33 payments
- Nancy Holekamp Chesterfield, MO Named on 28 payments
- Stephen Huddleston Germantown, TN Named on 27 payments
- Matthew Ohr Columbus, OH Named on 25 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.